
KBBTF
US listing · $24.1M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2022 | After the close | — | -9.44 | — |
| Aug 11, 2022 | After the close | — | -11.73 | — |
| May 12, 2022 | After the close | — | -14.30 | — |
| Feb 13, 2022 | After the close | — | -14.96 | — |
| Nov 11, 2021 | After the close | — | -12.65 | — |
| Aug 11, 2021 | After the close | — | -14.39 | — |
| May 12, 2021 | After the close | — | -15.48 | — |
| Feb 11, 2021 | After the close | — | -12.84 | — |
| Nov 12, 2020 | After the close | — | -14.48 | — |
| Aug 12, 2020 | After the close | — | -12.77 | — |
| May 13, 2020 | After the close | — | -16.87 | — |
| Feb 12, 2020 | After the close | — | -19.09 | — |
| Nov 13, 2019 | After the close | 0.00 | -0.18 | — |
| Aug 8, 2019 |
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a…
| After the close |
| 0.00 |
| -0.18 |
| — |
| May 9, 2019 | After the close | 0.00 | -0.16 | — |
| Feb 12, 2019 | After the close | 0.00 | -0.15 | — |
| Nov 13, 2018 | After the close | 0.00 | -0.20 | — |
| Aug 13, 2018 | After the close | 0.00 | -0.18 | — |
| May 14, 2018 | After the close | 0.00 | -0.16 | — |
| Feb 12, 2018 | After the close | — | -17.13 | — |